Aptar Digital Health has entered into a partnership with Enable Injections, Inc. to provide a companion digital platform that will run alongside Enable’s enFuse® On‑Body Delivery System. The platform will guide patients and caregivers through the injection process, capture treatment data, and offer training modules, patient‑reported outcomes, and symptom tracking. By integrating digital support with a large‑volume biologic delivery device, Aptar expands its digital health footprint and creates a new recurring revenue stream that complements its existing drug‑delivery component business.
Continue reading for full analysis...
AptarGroup’s Unidose Powder Nasal Delivery System was deployed in the Phase II clinical study of ENA Respiratory’s investigational nasal spray, INNA‑051, beginning on March 19 2026. The study will assess the safety and efficacy of the virus‑agnostic spray, which is designed to activate local innate immune defenses and reduce the impact of symptomatic viral respiratory infections.
Continue reading for full analysis...
AptarGroup, Inc. (NYSE:ATR) announced on March 17, 2026 that Gael Touya, a long‑time executive with more than 30 years at the company, will become President and Chief Executive Officer effective September 1, 2026. Touya most recently served as Aptar Pharma President and will succeed Stephan B. Tanda, who has led the company since 2017 and will retire from the Board by the end of 2026.
Continue reading for full analysis...